Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer

被引：0
|
作者：
Zammarrelli, William [1 ]
Ma, Weining [1 ]
Espino, Kevin [2 ]
Yeoshoua, Effi [1 ]
Ehmann, Sarah [1 ]
Zhou, Qin [1 ]
Iasonos, Alexia [1 ]
Abu-Rustum, Nadeem [1 ]
Aghajanian, Carol [1 ]
Green, Angela [1 ]
Rubinstein, Maria [1 ]
Makker, Vicky [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] NYU Langone Hosp, Baldwin, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1103
引用
收藏
页码：S79 / S80
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD EXPERIENCE AND COMMON ADVERSE EVENTS WHEN USING COMBINATION LENVATINIB AND PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT UTERINE CANCER
    Zammarrelli, William
    Espino, Kevin
    Yeoshoua, Effi
    Ehmann, Sarah
    Rubinstein, Maria
    Green, Angela
    Makker, Vicky
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A111 - A112
  • [2] Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Zammarrelli, William A.
    Ma, Weining
    Espino, Kevin
    Gordhandas, Sushmita
    Yeoshoua, Effi
    Ehmann, Sarah
    Zhou, Qin
    Iasonos, Alexia
    Abu-Rustum, Nadeem R.
    Aghajanian, Carol
    Green, Angela K.
    Rubinstein, Maria M.
    Makker, Vicky
    GYNECOLOGIC ONCOLOGY, 2023, 178 : 27 - 35
  • [3] Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA
    Wada, Keiko
    Zhang, Jingchuan
    Lee, Inyoung
    Wang, Yi
    Near, Aimee
    Prabhu, Vimalanand S.
    FUTURE ONCOLOGY, 2024, 20 (05) : 257 - 267
  • [4] Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea
    Kim, Junhwan
    Noh, Joseph J.
    Lee, Tae Kyoung
    Kim, Se Ik
    Lee, Jung-Yun
    Lee, Jeong-Won
    Kim, Jae-Weon
    GYNECOLOGIC ONCOLOGY, 2022, 165 (02) : 369 - 375
  • [5] Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database
    Wang, Shiqiao
    Ren, Guizhi
    Pan, Heng
    Chen, Jiayi
    Huang, Jiayu
    Mei, Qinghua
    Li, Zhongze
    Zou, Guosheng
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [6] Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab
    Pawsey, A.
    Mahalingam, P.
    Senthivel, N.
    Ramessur, A.
    Turnbull, E.
    Usman, S.
    Browne, R.
    Patel, A.
    Stewart, A.
    Tookman, L.
    Counsell, N.
    Miller, R.
    Nicum, S.
    Eminowicz, G.
    CLINICAL ONCOLOGY, 2025, 37
  • [7] The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study
    Jinbin Chen
    Peiyao Xiong
    Man Nie
    Yangxun Pan
    Juncheng Wang
    Dandan Hu
    Zhongguo Zhou
    Yaojun Zhang
    Minshan Chen
    Li Xu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2491 - 2500
  • [8] The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study
    Chen, Jinbin
    Xiong, Peiyao
    Nie, Man
    Pan, Yangxun
    Wang, Juncheng
    Hu, Dandan
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Xu, Li
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2491 - 2500
  • [9] Treatment outcomes in Uterine Sarcomas: A Real-world experience
    Gy, S.
    Rai, B.
    Dey, T.
    Srinivasan, R.
    Jain, V.
    Suri, V.
    Bagga, R.
    Ghoshal, S.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1155 - S1156
  • [10] Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
    Amrith, B. P.
    Sharma, M.
    Singh, H.
    Koyyala, V. P. B.
    Joga, S.
    Batra, U.
    ANNALS OF ONCOLOGY, 2022, 33 : S1479 - S1480
12345